172 related articles for article (PubMed ID: 9408013)
21. Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal.
Legnani C; Mattarozzi S; Cini M; Cosmi B; Favaretto E; Palareti G
Br J Haematol; 2006 Jul; 134(2):227-32. PubMed ID: 16846482
[TBL] [Abstract][Full Text] [Related]
22. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044
[TBL] [Abstract][Full Text] [Related]
23. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.
den Heijer M; Koster T; Blom HJ; Bos GM; Briet E; Reitsma PH; Vandenbroucke JP; Rosendaal FR
N Engl J Med; 1996 Mar; 334(12):759-62. PubMed ID: 8592549
[TBL] [Abstract][Full Text] [Related]
24. Multicentric evaluation of a new assay for prothrombin fragment F1+2 determination.
Bruhn HD; Conard J; Mannucci M; Monteagudo J; Pelzer H; Reverter JC; Samama M; Tripodi A; Wagner C
Thromb Haemost; 1992 Oct; 68(4):413-7. PubMed ID: 1448772
[TBL] [Abstract][Full Text] [Related]
25. Association between prothrombin activation fragment (F1.2), cerebral ischemia (S-100beta) and international normalized ratio (INR) in patients with ventricular assisted devices.
Joshi A; Magder LS; Kon Z; Kallam S; Kwon M; Sangrampurkar R; Pierson R; Poston R
Interact Cardiovasc Thorac Surg; 2007 Jun; 6(3):323-7. PubMed ID: 17669856
[TBL] [Abstract][Full Text] [Related]
26. Oral anticoagulant therapy in venous thromboembolism.
Cosmi B; Palareti G
Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
[TBL] [Abstract][Full Text] [Related]
27. Hyperhomocysteinemia in inflammatory bowel disease patients without past intestinal resections: correlations with cobalamin, pyridoxine, folate concentrations, acute phase reactants, disease activity, and prior thromboembolic complications.
Erzin Y; Uzun H; Celik AF; Aydin S; Dirican A; Uzunismail H
J Clin Gastroenterol; 2008; 42(5):481-6. PubMed ID: 18344891
[TBL] [Abstract][Full Text] [Related]
28. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin.
Brouwer JL; Lijfering WM; Ten Kate MK; Kluin-Nelemans HC; Veeger NJ; van der Meer J
Thromb Haemost; 2009 Jan; 101(1):93-9. PubMed ID: 19132194
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of markers of thrombin generation in the acute and chronic phases of non cardioembolic ischemic stroke.
Soncini M; Gasparini P; Lorena M; Motta A; Cimminiello C
Minerva Cardioangiol; 2000 Nov; 48(11):349-56. PubMed ID: 11214426
[TBL] [Abstract][Full Text] [Related]
30. [Evaluation of plasma prothrombin fragment 1+2 in healthy donors and thrombotic diseases].
Kawai Y; Shiomi T; Ono H; Katagiri H; Uchida R; Sugisaki N; Watanabe K
Rinsho Byori; 1994 Jan; 42(1):57-62. PubMed ID: 8107284
[TBL] [Abstract][Full Text] [Related]
31. Parameters of haemostasis during acute venous thrombosis.
Reiter W; Ehrensberger H; Steinbrückner B; Keller F
Thromb Haemost; 1995 Aug; 74(2):596-601. PubMed ID: 8584990
[TBL] [Abstract][Full Text] [Related]
32. [Changes in antithrombin III, prothrombin fragment 1 + 2 and thrombin-antithrombin III complex following implantation of a coronary Palmaz-Schatz stent].
Dittel M; Haushofer A; Spiel R; Halbmayer WM; Prachar H; Fischer M; Mlczoch J
Z Kardiol; 1995 Jan; 84(1):22-9. PubMed ID: 7863710
[TBL] [Abstract][Full Text] [Related]
33. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
Falciani M; Gori AM; Fedi S; Chiarugi L; Simonetti I; Dabizzi RP; Prisco D; Pepe G; Abbate R; Gensini GF; Neri Serneri GG
Thromb Haemost; 1998 Mar; 79(3):495-9. PubMed ID: 9531029
[TBL] [Abstract][Full Text] [Related]
34. Prothrombin activation fragment 1 + 2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis.
Kienast J; Thompson SG; Raskino C; Pelzer H; Fechtrup C; Ostermann H; van de Loo J
Thromb Haemost; 1993 Oct; 70(4):550-3. PubMed ID: 8115978
[TBL] [Abstract][Full Text] [Related]
35. Inhibition rather than enhancement of hemostatic system activation during initiation of oral anticoagulant treatment.
Kyrle PA; Brockmeier J; Weltermann A; Eichinger S; Speiser W; Lechner K; Eichler HG
Thromb Haemost; 1997 Apr; 77(4):685-9. PubMed ID: 9134643
[TBL] [Abstract][Full Text] [Related]
36. Haemostatic and lipid determinants of prothrombin fragment F1.2 and D-dimer in plasma.
MacCallum PK; Cooper JA; Martin J; Howarth DJ; Meade TW; Miller GJ
Thromb Haemost; 2000 Mar; 83(3):421-6. PubMed ID: 10744148
[TBL] [Abstract][Full Text] [Related]
37. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden.
Eichinger S; Weltermann A; Philipp K; Hafner E; Kaider A; Kittl EM; Brenner B; Mannhalter C; Lechner K; Kyrle PA
Thromb Haemost; 1999 Oct; 82(4):1232-6. PubMed ID: 10544904
[TBL] [Abstract][Full Text] [Related]
38. Markers of hemostatic system activation in pulmonary embolism. Changes during and after cessation of anticoagulant treatment.
de Raucourt E; Meyer G; Landais P; Gouaref Z; Morinet P; Monge F; Sors H; Fischer AM
Blood Coagul Fibrinolysis; 2000 Apr; 11(3):249-53. PubMed ID: 10870805
[TBL] [Abstract][Full Text] [Related]
39. Reduced inhibition of activated prothrombin by heparin and venous thromboembolism: heparin resistance revisited.
Legnani C; Preda L; Palareti G; Lunghi B; Rossi E; Coccheri S
Haematologica; 2002 Feb; 87(2):182-8. PubMed ID: 11836169
[TBL] [Abstract][Full Text] [Related]
40. [Hyperhomocysteinemia--one of the factors underlying thrombotic complications in patients with chronic myeloproliferative diseases].
Sokolova MA; Khoroshko ND; Tsvetaeva NV; Turkina AG; Levina AA; Mamukova IuI; Rokhnianskaia AA; Sudarikov AB; Romanova EA; Vasil'ev SA; Sukhanova GA; Orel EB; Rudakova VE; Tutaeva VV; Manakova TE; Semenova EA; Kulikov SM
Ter Arkh; 2007; 79(12):57-62. PubMed ID: 18220034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
